FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:OAZ1-YBX2

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: OAZ1-YBX2
FusionPDB ID: 61292
FusionGDB2.0 ID: 61292
HgeneTgene
Gene symbol

OAZ1

YBX2

Gene ID

4946

51087

Gene nameornithine decarboxylase antizyme 1Y-box binding protein 2
SynonymsAZ1|AZI|OAZCONTRIN|CSDA3|DBPC|MSY2
Cytomap

19p13.3

17p13.1

Type of geneprotein-codingprotein-coding
Descriptionornithine decarboxylase antizyme 1ODC-Azantizyme 1Y-box-binding protein 2DNA-binding protein Cepididymis secretory sperm binding proteingerm cell specific Y-box binding protein
Modification date2020031320200313
UniProtAcc..
Ensembl transtripts involved in fusion geneENST idsENST00000322297, ENST00000582888, 
ENST00000583542, ENST00000602676, 
ENST00000588673, 
ENST00000570627, 
ENST00000007699, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score19 X 7 X 8=10646 X 4 X 5=120
# samples 176
** MAII scorelog2(17/1064*10)=-2.64589149936349
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
log2(6/120*10)=-1
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: OAZ1 [Title/Abstract] AND YBX2 [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: OAZ1 [Title/Abstract] AND YBX2 [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)OAZ1(2269743)-YBX2(7195378), # samples:3
Anticipated loss of major functional domain due to fusion event.OAZ1-YBX2 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
OAZ1-YBX2 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
OAZ1-YBX2 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
OAZ1-YBX2 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
HgeneOAZ1

GO:0045732

positive regulation of protein catabolic process

17900240



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr19:2269743/chr17:7195378)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across OAZ1 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across YBX2 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000582888OAZ1chr192269743+ENST00000007699YBX2chr177195378-1450259891018309
ENST00000602676OAZ1chr192269743+ENST00000007699YBX2chr177195378-141622555984309
ENST00000322297OAZ1chr192269743+ENST00000007699YBX2chr177195378-141522454983309
ENST00000583542OAZ1chr192269743+ENST00000007699YBX2chr177195378-141122050979309

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000582888ENST00000007699OAZ1chr192269743+YBX2chr177195378-0.0852372350.9147628
ENST00000602676ENST00000007699OAZ1chr192269743+YBX2chr177195378-0.0800527860.91994727
ENST00000322297ENST00000007699OAZ1chr192269743+YBX2chr177195378-0.081089030.918911
ENST00000583542ENST00000007699OAZ1chr192269743+YBX2chr177195378-0.080785930.91921407

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for OAZ1-YBX2

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
OAZ1chr192269743YBX2chr17719537822043KPSATIHASRTMPLLSLHSRGGSSSE
OAZ1chr192269743YBX2chr17719537822443KPSATIHASRTMPLLSLHSRGGSSSE
OAZ1chr192269743YBX2chr17719537822543KPSATIHASRTMPLLSLHSRGGSSSE
OAZ1chr192269743YBX2chr17719537825943KPSATIHASRTMPLLSLHSRGGSSSE

Top

Potential FusionNeoAntigen Information of OAZ1-YBX2 in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
OAZ1-YBX2_2269743_7195378.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
OAZ1-YBX2chr192269743chr177195378224HLA-B15:17RTMPLLSL0.99920.8941917
OAZ1-YBX2chr192269743chr177195378224HLA-B15:16RTMPLLSL0.99860.7326917
OAZ1-YBX2chr192269743chr177195378224HLA-A30:08RTMPLLSL0.98420.7227917
OAZ1-YBX2chr192269743chr177195378224HLA-B27:04SRTMPLLSL0.99990.7183817
OAZ1-YBX2chr192269743chr177195378224HLA-B27:02SRTMPLLSL0.99990.5093817
OAZ1-YBX2chr192269743chr177195378224HLA-B27:05SRTMPLLSL0.99990.7756817
OAZ1-YBX2chr192269743chr177195378224HLA-B39:01SRTMPLLSL0.99950.923817
OAZ1-YBX2chr192269743chr177195378224HLA-B39:06SRTMPLLSL0.99920.7229817
OAZ1-YBX2chr192269743chr177195378224HLA-B38:02SRTMPLLSL0.99890.9626817
OAZ1-YBX2chr192269743chr177195378224HLA-B39:01IHASRTMPL0.99880.8557514
OAZ1-YBX2chr192269743chr177195378224HLA-B38:01SRTMPLLSL0.99880.9536817
OAZ1-YBX2chr192269743chr177195378224HLA-B14:01SRTMPLLSL0.99830.6856817
OAZ1-YBX2chr192269743chr177195378224HLA-B14:02SRTMPLLSL0.99830.6856817
OAZ1-YBX2chr192269743chr177195378224HLA-B39:06IHASRTMPL0.99690.7706514
OAZ1-YBX2chr192269743chr177195378224HLA-B38:02IHASRTMPL0.99540.9192514
OAZ1-YBX2chr192269743chr177195378224HLA-B38:01IHASRTMPL0.99490.898514
OAZ1-YBX2chr192269743chr177195378224HLA-B14:01IHASRTMPL0.99030.6079514
OAZ1-YBX2chr192269743chr177195378224HLA-B14:02IHASRTMPL0.99030.6079514
OAZ1-YBX2chr192269743chr177195378224HLA-A30:08RTMPLLSLH0.98880.5727918
OAZ1-YBX2chr192269743chr177195378224HLA-B15:10IHASRTMPL0.98140.5096514
OAZ1-YBX2chr192269743chr177195378224HLA-B35:03HASRTMPLL0.96540.7905615
OAZ1-YBX2chr192269743chr177195378224HLA-B15:16RTMPLLSLH0.96320.5985918
OAZ1-YBX2chr192269743chr177195378224HLA-B15:37IHASRTMPL0.93050.5066514
OAZ1-YBX2chr192269743chr177195378224HLA-B35:04HASRTMPLL0.87510.8547615
OAZ1-YBX2chr192269743chr177195378224HLA-B35:02HASRTMPLL0.87510.8547615
OAZ1-YBX2chr192269743chr177195378224HLA-B15:18SRTMPLLSL0.81960.6643817
OAZ1-YBX2chr192269743chr177195378224HLA-B15:37SRTMPLLSL0.81760.6176817
OAZ1-YBX2chr192269743chr177195378224HLA-B15:18IHASRTMPL0.80830.636514
OAZ1-YBX2chr192269743chr177195378224HLA-B27:04SRTMPLLSLH0.99990.6971818
OAZ1-YBX2chr192269743chr177195378224HLA-B27:05SRTMPLLSLH0.99990.8024818
OAZ1-YBX2chr192269743chr177195378224HLA-B27:05ASRTMPLLSL0.99760.8282717
OAZ1-YBX2chr192269743chr177195378224HLA-B27:02ASRTMPLLSL0.99750.514717
OAZ1-YBX2chr192269743chr177195378224HLA-B27:04ASRTMPLLSL0.99720.7361717
OAZ1-YBX2chr192269743chr177195378224HLA-B38:02IHASRTMPLL0.99310.9249515
OAZ1-YBX2chr192269743chr177195378224HLA-B38:01IHASRTMPLL0.9930.9051515
OAZ1-YBX2chr192269743chr177195378224HLA-A30:08ASRTMPLLSL0.98160.6852717
OAZ1-YBX2chr192269743chr177195378224HLA-B39:01TIHASRTMPL0.77070.8715414
OAZ1-YBX2chr192269743chr177195378224HLA-B27:07HASRTMPLLSL0.99880.5606617
OAZ1-YBX2chr192269743chr177195378224HLA-A74:03RTMPLLSLHSR0.99730.5772920
OAZ1-YBX2chr192269743chr177195378224HLA-A74:09RTMPLLSLHSR0.99730.5772920
OAZ1-YBX2chr192269743chr177195378224HLA-A74:11RTMPLLSLHSR0.99730.5772920
OAZ1-YBX2chr192269743chr177195378224HLA-A31:02RTMPLLSLHSR0.99180.5751920
OAZ1-YBX2chr192269743chr177195378224HLA-A30:08RTMPLLSLHSR0.99020.687920
OAZ1-YBX2chr192269743chr177195378224HLA-C15:04RTMPLLSL10.9128917
OAZ1-YBX2chr192269743chr177195378224HLA-C15:06RTMPLLSL0.99990.9468917
OAZ1-YBX2chr192269743chr177195378224HLA-C03:08RTMPLLSL0.99960.9257917
OAZ1-YBX2chr192269743chr177195378224HLA-B27:14SRTMPLLSL0.99990.7848817
OAZ1-YBX2chr192269743chr177195378224HLA-C15:04HASRTMPLL0.99980.8009615
OAZ1-YBX2chr192269743chr177195378224HLA-C03:19HASRTMPLL0.99970.9686615
OAZ1-YBX2chr192269743chr177195378224HLA-C03:08HASRTMPLL0.99970.8516615
OAZ1-YBX2chr192269743chr177195378224HLA-C15:06HASRTMPLL0.99970.8328615
OAZ1-YBX2chr192269743chr177195378224HLA-C03:07HASRTMPLL0.99970.8987615
OAZ1-YBX2chr192269743chr177195378224HLA-B39:09SRTMPLLSL0.99950.6262817
OAZ1-YBX2chr192269743chr177195378224HLA-B39:12SRTMPLLSL0.99940.9283817
OAZ1-YBX2chr192269743chr177195378224HLA-C07:95SRTMPLLSL0.99930.6547817
OAZ1-YBX2chr192269743chr177195378224HLA-C07:05SRTMPLLSL0.99920.9665817
OAZ1-YBX2chr192269743chr177195378224HLA-B39:09IHASRTMPL0.99890.5853514
OAZ1-YBX2chr192269743chr177195378224HLA-C07:27SRTMPLLSL0.99890.9349817
OAZ1-YBX2chr192269743chr177195378224HLA-B39:05SRTMPLLSL0.99870.9081817
OAZ1-YBX2chr192269743chr177195378224HLA-C07:13SRTMPLLSL0.99860.8886817
OAZ1-YBX2chr192269743chr177195378224HLA-B39:12IHASRTMPL0.99860.8595514
OAZ1-YBX2chr192269743chr177195378224HLA-C04:06HASRTMPLL0.99840.8456615
OAZ1-YBX2chr192269743chr177195378224HLA-C07:29SRTMPLLSL0.99840.9329817
OAZ1-YBX2chr192269743chr177195378224HLA-B27:03SRTMPLLSL0.99730.8234817
OAZ1-YBX2chr192269743chr177195378224HLA-C08:13HASRTMPLL0.99670.9068615
OAZ1-YBX2chr192269743chr177195378224HLA-C08:04HASRTMPLL0.99670.9068615
OAZ1-YBX2chr192269743chr177195378224HLA-B39:05IHASRTMPL0.99520.8452514
OAZ1-YBX2chr192269743chr177195378224HLA-C03:14HASRTMPLL0.98720.9266615
OAZ1-YBX2chr192269743chr177195378224HLA-C12:12HASRTMPLL0.98550.9052615
OAZ1-YBX2chr192269743chr177195378224HLA-C06:03HASRTMPLL0.98480.974615
OAZ1-YBX2chr192269743chr177195378224HLA-C12:04HASRTMPLL0.98450.9687615
OAZ1-YBX2chr192269743chr177195378224HLA-C02:06HASRTMPLL0.98420.8945615
OAZ1-YBX2chr192269743chr177195378224HLA-C07:46SRTMPLLSL0.98340.7835817
OAZ1-YBX2chr192269743chr177195378224HLA-C08:03HASRTMPLL0.96670.9647615
OAZ1-YBX2chr192269743chr177195378224HLA-C15:04RTMPLLSLH0.96470.9008918
OAZ1-YBX2chr192269743chr177195378224HLA-B73:01SRTMPLLSL0.95770.6028817
OAZ1-YBX2chr192269743chr177195378224HLA-C07:80SRTMPLLSL0.94630.8959817
OAZ1-YBX2chr192269743chr177195378224HLA-C07:67SRTMPLLSL0.94630.8959817
OAZ1-YBX2chr192269743chr177195378224HLA-C07:19SRTMPLLSL0.91890.6323817
OAZ1-YBX2chr192269743chr177195378224HLA-C07:10SRTMPLLSL0.87960.9251817
OAZ1-YBX2chr192269743chr177195378224HLA-B35:12HASRTMPLL0.87510.8547615
OAZ1-YBX2chr192269743chr177195378224HLA-C07:13IHASRTMPL0.77010.8777514
OAZ1-YBX2chr192269743chr177195378224HLA-C07:29IHASRTMPL0.73670.8918514
OAZ1-YBX2chr192269743chr177195378224HLA-B14:03IHASRTMPL0.71970.7402514
OAZ1-YBX2chr192269743chr177195378224HLA-C07:67IHASRTMPL0.6980.908514
OAZ1-YBX2chr192269743chr177195378224HLA-C07:80IHASRTMPL0.6980.908514
OAZ1-YBX2chr192269743chr177195378224HLA-B14:03SRTMPLLSL0.68410.7488817
OAZ1-YBX2chr192269743chr177195378224HLA-C07:10IHASRTMPL0.63720.9246514
OAZ1-YBX2chr192269743chr177195378224HLA-C07:46IHASRTMPL0.62970.8654514
OAZ1-YBX2chr192269743chr177195378224HLA-B15:04RTMPLLSLH0.53220.7554918
OAZ1-YBX2chr192269743chr177195378224HLA-C12:16SRTMPLLSL0.4410.9475817
OAZ1-YBX2chr192269743chr177195378224HLA-C12:16IHASRTMPL0.05060.9225514
OAZ1-YBX2chr192269743chr177195378224HLA-B27:14SRTMPLLSLH0.99990.7962818
OAZ1-YBX2chr192269743chr177195378224HLA-B27:03SRTMPLLSLH0.99920.8496818
OAZ1-YBX2chr192269743chr177195378224HLA-B14:03TIHASRTMPL0.96860.7708414
OAZ1-YBX2chr192269743chr177195378224HLA-B27:03ASRTMPLLSL0.93750.8597717
OAZ1-YBX2chr192269743chr177195378224HLA-A31:01RTMPLLSLHSR0.99730.5519920
OAZ1-YBX2chr192269743chr177195378224HLA-C15:09RTMPLLSL10.9128917
OAZ1-YBX2chr192269743chr177195378224HLA-C15:05RTMPLLSL0.99990.907917
OAZ1-YBX2chr192269743chr177195378224HLA-C15:02RTMPLLSL0.99990.8877917
OAZ1-YBX2chr192269743chr177195378224HLA-C16:02RTMPLLSL0.99960.9914917
OAZ1-YBX2chr192269743chr177195378224HLA-C03:05RTMPLLSL0.99940.9102917
OAZ1-YBX2chr192269743chr177195378224HLA-A32:01RTMPLLSL0.99860.9503917
OAZ1-YBX2chr192269743chr177195378224HLA-C16:01HASRTMPL0.99660.9605614
OAZ1-YBX2chr192269743chr177195378224HLA-B07:13RTMPLLSL0.86460.8824917
OAZ1-YBX2chr192269743chr177195378224HLA-B27:06SRTMPLLSL0.99990.6887817
OAZ1-YBX2chr192269743chr177195378224HLA-B27:08SRTMPLLSL0.99990.7253817
OAZ1-YBX2chr192269743chr177195378224HLA-B27:10SRTMPLLSL0.99990.8344817
OAZ1-YBX2chr192269743chr177195378224HLA-C15:09HASRTMPLL0.99980.8009615
OAZ1-YBX2chr192269743chr177195378224HLA-B27:09SRTMPLLSL0.99980.765817
OAZ1-YBX2chr192269743chr177195378224HLA-C03:05HASRTMPLL0.99970.8906615
OAZ1-YBX2chr192269743chr177195378224HLA-C15:05HASRTMPLL0.99960.8084615
OAZ1-YBX2chr192269743chr177195378224HLA-C03:03HASRTMPLL0.99960.9711615
OAZ1-YBX2chr192269743chr177195378224HLA-C03:04HASRTMPLL0.99960.9711615
OAZ1-YBX2chr192269743chr177195378224HLA-C03:17HASRTMPLL0.99960.9396615
OAZ1-YBX2chr192269743chr177195378224HLA-C15:02HASRTMPLL0.99950.7779615
OAZ1-YBX2chr192269743chr177195378224HLA-B39:31SRTMPLLSL0.99950.9247817
OAZ1-YBX2chr192269743chr177195378224HLA-B39:02SRTMPLLSL0.99940.9324817
OAZ1-YBX2chr192269743chr177195378224HLA-C07:01SRTMPLLSL0.99930.626817
OAZ1-YBX2chr192269743chr177195378224HLA-B38:05SRTMPLLSL0.99880.9536817
OAZ1-YBX2chr192269743chr177195378224HLA-B39:31IHASRTMPL0.99870.8556514
OAZ1-YBX2chr192269743chr177195378224HLA-C16:04HASRTMPLL0.99830.9504615
OAZ1-YBX2chr192269743chr177195378224HLA-C07:17SRTMPLLSL0.99740.96817
OAZ1-YBX2chr192269743chr177195378224HLA-B38:05IHASRTMPL0.99490.898514
OAZ1-YBX2chr192269743chr177195378224HLA-C03:06HASRTMPLL0.99250.9698615
OAZ1-YBX2chr192269743chr177195378224HLA-C06:08SRTMPLLSL0.99180.9773817
OAZ1-YBX2chr192269743chr177195378224HLA-A30:01RTMPLLSLH0.99050.7428918
OAZ1-YBX2chr192269743chr177195378224HLA-C12:03HASRTMPLL0.98780.9468615
OAZ1-YBX2chr192269743chr177195378224HLA-C16:01HASRTMPLL0.98670.9602615
OAZ1-YBX2chr192269743chr177195378224HLA-C16:02HASRTMPLL0.98640.9781615
OAZ1-YBX2chr192269743chr177195378224HLA-C02:10HASRTMPLL0.97950.9554615
OAZ1-YBX2chr192269743chr177195378224HLA-C02:02HASRTMPLL0.97950.9554615
OAZ1-YBX2chr192269743chr177195378224HLA-B58:06RTMPLLSLH0.96830.7317918
OAZ1-YBX2chr192269743chr177195378224HLA-C08:01HASRTMPLL0.96670.9647615
OAZ1-YBX2chr192269743chr177195378224HLA-C15:09RTMPLLSLH0.96470.9008918
OAZ1-YBX2chr192269743chr177195378224HLA-B35:13HASRTMPLL0.96280.7995615
OAZ1-YBX2chr192269743chr177195378224HLA-B07:13HASRTMPLL0.96040.8383615
OAZ1-YBX2chr192269743chr177195378224HLA-C07:22SRTMPLLSL0.95870.7336817
OAZ1-YBX2chr192269743chr177195378224HLA-B15:09IHASRTMPL0.95610.528514
OAZ1-YBX2chr192269743chr177195378224HLA-B15:09SRTMPLLSL0.95420.5881817
OAZ1-YBX2chr192269743chr177195378224HLA-C07:02SRTMPLLSL0.94630.8959817
OAZ1-YBX2chr192269743chr177195378224HLA-C07:04SRTMPLLSL0.91780.9337817
OAZ1-YBX2chr192269743chr177195378224HLA-B35:09HASRTMPLL0.87510.8547615
OAZ1-YBX2chr192269743chr177195378224HLA-B39:11SRTMPLLSL0.84750.7629817
OAZ1-YBX2chr192269743chr177195378224HLA-C17:01HASRTMPLL0.7940.8542615
OAZ1-YBX2chr192269743chr177195378224HLA-C03:67SRTMPLLSL0.7840.9762817
OAZ1-YBX2chr192269743chr177195378224HLA-C07:17IHASRTMPL0.72720.9334514
OAZ1-YBX2chr192269743chr177195378224HLA-C07:02IHASRTMPL0.6980.908514
OAZ1-YBX2chr192269743chr177195378224HLA-C06:06SRTMPLLSL0.64640.9878817
OAZ1-YBX2chr192269743chr177195378224HLA-B39:11IHASRTMPL0.6070.6096514
OAZ1-YBX2chr192269743chr177195378224HLA-C03:67IHASRTMPL0.55760.9419514
OAZ1-YBX2chr192269743chr177195378224HLA-C07:04IHASRTMPL0.55280.8886514
OAZ1-YBX2chr192269743chr177195378224HLA-C06:17SRTMPLLSL0.53850.9892817
OAZ1-YBX2chr192269743chr177195378224HLA-C06:02SRTMPLLSL0.53850.9892817
OAZ1-YBX2chr192269743chr177195378224HLA-C06:06IHASRTMPL0.19850.9643514
OAZ1-YBX2chr192269743chr177195378224HLA-B27:08SRTMPLLSLH0.99990.7082818
OAZ1-YBX2chr192269743chr177195378224HLA-B27:10SRTMPLLSLH0.99990.8367818
OAZ1-YBX2chr192269743chr177195378224HLA-B27:10ASRTMPLLSL0.99750.866717
OAZ1-YBX2chr192269743chr177195378224HLA-B27:08ASRTMPLLSL0.9970.7626717
OAZ1-YBX2chr192269743chr177195378224HLA-B27:06ASRTMPLLSL0.99550.7406717
OAZ1-YBX2chr192269743chr177195378224HLA-B27:09ASRTMPLLSL0.99460.8114717
OAZ1-YBX2chr192269743chr177195378224HLA-B38:05IHASRTMPLL0.9930.9051515
OAZ1-YBX2chr192269743chr177195378224HLA-B27:06HASRTMPLLSL0.99970.7122617
OAZ1-YBX2chr192269743chr177195378224HLA-B27:08HASRTMPLLSL0.99930.7194617
OAZ1-YBX2chr192269743chr177195378224HLA-B27:09HASRTMPLLSL0.99930.7642617
OAZ1-YBX2chr192269743chr177195378224HLA-A74:01RTMPLLSLHSR0.99730.5772920
OAZ1-YBX2chr192269743chr177195378224HLA-A30:01RTMPLLSLHSR0.99150.7944920

Top

Potential FusionNeoAntigen Information of OAZ1-YBX2 in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
OAZ1-YBX2_2269743_7195378.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
OAZ1-YBX2chr192269743chr177195378224DRB1-0415TMPLLSLHSRGGSSS1025
OAZ1-YBX2chr192269743chr177195378224DRB1-0436TMPLLSLHSRGGSSS1025
OAZ1-YBX2chr192269743chr177195378224DRB1-0701PSATIHASRTMPLLS116
OAZ1-YBX2chr192269743chr177195378224DRB1-0703PSATIHASRTMPLLS116
OAZ1-YBX2chr192269743chr177195378224DRB1-0705PSATIHASRTMPLLS116
OAZ1-YBX2chr192269743chr177195378224DRB1-0706PSATIHASRTMPLLS116
OAZ1-YBX2chr192269743chr177195378224DRB1-0707PSATIHASRTMPLLS116
OAZ1-YBX2chr192269743chr177195378224DRB1-0708PSATIHASRTMPLLS116
OAZ1-YBX2chr192269743chr177195378224DRB1-0709PSATIHASRTMPLLS116
OAZ1-YBX2chr192269743chr177195378224DRB1-0712PSATIHASRTMPLLS116
OAZ1-YBX2chr192269743chr177195378224DRB1-0713PSATIHASRTMPLLS116
OAZ1-YBX2chr192269743chr177195378224DRB1-0714PSATIHASRTMPLLS116
OAZ1-YBX2chr192269743chr177195378224DRB1-0715PSATIHASRTMPLLS116
OAZ1-YBX2chr192269743chr177195378224DRB1-0716PSATIHASRTMPLLS116
OAZ1-YBX2chr192269743chr177195378224DRB1-0717PSATIHASRTMPLLS116
OAZ1-YBX2chr192269743chr177195378224DRB1-0719PSATIHASRTMPLLS116
OAZ1-YBX2chr192269743chr177195378224DRB1-0901PSATIHASRTMPLLS116
OAZ1-YBX2chr192269743chr177195378224DRB1-0901SATIHASRTMPLLSL217
OAZ1-YBX2chr192269743chr177195378224DRB1-0904PSATIHASRTMPLLS116
OAZ1-YBX2chr192269743chr177195378224DRB1-0904SATIHASRTMPLLSL217
OAZ1-YBX2chr192269743chr177195378224DRB1-0904KPSATIHASRTMPLL015
OAZ1-YBX2chr192269743chr177195378224DRB1-0905PSATIHASRTMPLLS116
OAZ1-YBX2chr192269743chr177195378224DRB1-0906PSATIHASRTMPLLS116
OAZ1-YBX2chr192269743chr177195378224DRB1-0906SATIHASRTMPLLSL217
OAZ1-YBX2chr192269743chr177195378224DRB1-0906KPSATIHASRTMPLL015
OAZ1-YBX2chr192269743chr177195378224DRB1-0907PSATIHASRTMPLLS116
OAZ1-YBX2chr192269743chr177195378224DRB1-0907SATIHASRTMPLLSL217
OAZ1-YBX2chr192269743chr177195378224DRB1-0909PSATIHASRTMPLLS116
OAZ1-YBX2chr192269743chr177195378224DRB1-0909SATIHASRTMPLLSL217
OAZ1-YBX2chr192269743chr177195378224DRB1-1404PSATIHASRTMPLLS116
OAZ1-YBX2chr192269743chr177195378224DRB1-1410PSATIHASRTMPLLS116
OAZ1-YBX2chr192269743chr177195378224DRB1-1410SATIHASRTMPLLSL217
OAZ1-YBX2chr192269743chr177195378224DRB1-1428PSATIHASRTMPLLS116
OAZ1-YBX2chr192269743chr177195378224DRB1-1428SATIHASRTMPLLSL217
OAZ1-YBX2chr192269743chr177195378224DRB1-1439PSATIHASRTMPLLS116
OAZ1-YBX2chr192269743chr177195378224DRB1-1439SATIHASRTMPLLSL217
OAZ1-YBX2chr192269743chr177195378224DRB1-1450PSATIHASRTMPLLS116
OAZ1-YBX2chr192269743chr177195378224DRB1-1461PSATIHASRTMPLLS116
OAZ1-YBX2chr192269743chr177195378224DRB1-1471PSATIHASRTMPLLS116

Top

Fusion breakpoint peptide structures of OAZ1-YBX2

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
3278HASRTMPLLSLHSROAZ1YBX2chr192269743chr177195378224

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of OAZ1-YBX2

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN3278HASRTMPLLSLHSR-7.9962-8.1096
HLA-B14:023BVN3278HASRTMPLLSLHSR-5.70842-6.74372
HLA-B52:013W393278HASRTMPLLSLHSR-6.83737-6.95077
HLA-B52:013W393278HASRTMPLLSLHSR-4.4836-5.5189
HLA-A11:014UQ23278HASRTMPLLSLHSR-10.0067-10.1201
HLA-A11:014UQ23278HASRTMPLLSLHSR-9.03915-10.0745
HLA-A24:025HGA3278HASRTMPLLSLHSR-6.56204-6.67544
HLA-A24:025HGA3278HASRTMPLLSLHSR-5.42271-6.45801
HLA-B44:053DX83278HASRTMPLLSLHSR-7.85648-8.89178
HLA-B44:053DX83278HASRTMPLLSLHSR-5.3978-5.5112
HLA-A02:016TDR3278HASRTMPLLSLHSR-3.37154-4.40684

Top

Vaccine Design for the FusionNeoAntigens of OAZ1-YBX2

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
OAZ1-YBX2chr192269743chr177195378414TIHASRTMPLCAGCCGCGGCGGCAGCAGCAGTGAGAGGAA
OAZ1-YBX2chr192269743chr177195378514IHASRTMPLCCGCGGCGGCAGCAGCAGTGAGAGGAA
OAZ1-YBX2chr192269743chr177195378515IHASRTMPLLCCGCGGCGGCAGCAGCAGTGAGAGGAATGA
OAZ1-YBX2chr192269743chr177195378614HASRTMPLCGGCGGCAGCAGCAGTGAGAGGAA
OAZ1-YBX2chr192269743chr177195378615HASRTMPLLCGGCGGCAGCAGCAGTGAGAGGAATGA
OAZ1-YBX2chr192269743chr177195378617HASRTMPLLSLCGGCGGCAGCAGCAGTGAGAGGAATGACACCAA
OAZ1-YBX2chr192269743chr177195378717ASRTMPLLSLCGGCAGCAGCAGTGAGAGGAATGACACCAA
OAZ1-YBX2chr192269743chr177195378817SRTMPLLSLCAGCAGCAGTGAGAGGAATGACACCAA
OAZ1-YBX2chr192269743chr177195378818SRTMPLLSLHCAGCAGCAGTGAGAGGAATGACACCAAGGA
OAZ1-YBX2chr192269743chr177195378917RTMPLLSLCAGCAGTGAGAGGAATGACACCAA
OAZ1-YBX2chr192269743chr177195378918RTMPLLSLHCAGCAGTGAGAGGAATGACACCAAGGA
OAZ1-YBX2chr192269743chr177195378920RTMPLLSLHSRCAGCAGTGAGAGGAATGACACCAAGGAAGATGT

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
OAZ1-YBX2chr192269743chr177195378015KPSATIHASRTMPLLCCTAAGCCTGCACAGCCGCGGCGGCAGCAGCAGTGAGAGGAATGA
OAZ1-YBX2chr192269743chr177195378116PSATIHASRTMPLLSAAGCCTGCACAGCCGCGGCGGCAGCAGCAGTGAGAGGAATGACAC
OAZ1-YBX2chr192269743chr1771953781025TMPLLSLHSRGGSSSCAGTGAGAGGAATGACACCAAGGAAGATGTCTTTGTTCACCAGAC
OAZ1-YBX2chr192269743chr177195378217SATIHASRTMPLLSLCCTGCACAGCCGCGGCGGCAGCAGCAGTGAGAGGAATGACACCAA

Top

Information of the samples that have these potential fusion neoantigens of OAZ1-YBX2

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
LIHCOAZ1-YBX2chr192269743ENST00000322297chr177195378ENST00000007699TCGA-BC-A10Y-01A

Top

Potential target of CAR-T therapy development for OAZ1-YBX2

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to OAZ1-YBX2

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to OAZ1-YBX2

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource